Status:
COMPLETED
BETAEVAL Global - The New BETACONNECT Auto-injector : Adherence and EVALuation of Multiple Sclerosis Patients Treated With Betaferon
Lead Sponsor:
Bayer
Conditions:
Multiple Sclerosis, Relapsing Remitting
Eligibility:
All Genders
Brief Summary
Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as well as the challenge to achieve high adherence to treatment, evaluating the benefits of any new measure to...
Eligibility Criteria
Inclusion
- Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome.
- Patients must be on treatment with Betaferon or the decision to treat a patient with Betaferon has been made by the attending physician.
- Patient and attending physicians must have agreed on the usage of the BETACONNECT auto-injector device.
- Written informed consent must be obtained.
Exclusion
- Patients receiving any other disease modifying drug.
- Contraindications of Betaferon described in the Summary of Product Characteristics.
Key Trial Info
Start Date :
October 20 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 8 2016
Estimated Enrollment :
498 Patients enrolled
Trial Details
Trial ID
NCT02247310
Start Date
October 20 2014
End Date
November 8 2016
Last Update
November 7 2017
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations, Austria
2
Many Locations, Belgium
3
Many Locations, Bosnia and Herzegovina
4
Many Locations, Croatia